Affiliation:
1. School of International Pharmaceutical Business
2. Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
Abstract
Background:
Surgical site infections (SSIs) are one of the most common complications after pancreaticoduodenectomy (PD); however, the global prevalence and risk factors for SSIs after PD remain unknown.
Objectives:
To investigate the prevalence of and risk factors for SSIs after PD.
Methods:
The PubMed, Embase, Cochrane Library, Web of Science, and Science Direct databases were systematically searched from inception to 1 December 2022. Observational studies reporting adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of risk factors for SSIs in patients undergoing PD were included. Two independent reviewers in teams performed data extraction, risk of bias assessment, and level of evidence analysis. The pooled results were estimated using a random-effects model. The I
2 statistic and Q χ
2 statistic were used to assess heterogeneity. Funnel plots, Egger’s regression test, and the trim-and-fill method were used to determine publication bias. The primary outcomes were identifying risk factors for SSIs after PD. The secondary outcomes were the pooled prevalence rates of SSIs.
Results:
A total of 98 704 patients from 45 studies were included, and 80% of the studies were considered high quality. The estimated pooled prevalence of SSIs was 23% (0.19–0.27, I
2=97%). The prevalence of SSIs was found to be higher in Japan and lower in USA. Preoperative biliary stenting, higher body mass index (BMI), longer operation time, postoperative pancreatic fistula, soft pancreatic texture, perioperative blood transfusion, and cardiac disease were identified as significant risk factors for the development of SSIs after PD. Additionally, broad-spectrum antibiotics were a significant protective factor against SSIs. Subgroup analysis and sensitivity analysis showed that the results were robust.
Conclusion and relevance:
The prevalence of SSIs remains high and varies widely among regions. It is necessary to take effective preventive measures and carry out more prospective studies to further verify these results.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference78 articles.
1. Complications after pancreaticoduodenectomy;Simon;Surg Clin North Am,2021
2. Technical aspects in pancreaticoduodenectomy and therapeutic strategies for pancreatic cancer: history, current status, and future perspectives;Hori;Hepatobiliary Pancreat Dis Int,2022
3. Establishing a quantitative benchmark for morbidity in pancreatoduodenectomy using ACS-NSQIP, the Accordion Severity Grading System, and the Postoperative Morbidity Index;Vollmer;Ann Surg,2015
4. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs;Kirkland;Infect Control Hosp Epidemiol,1999
5. Unique predictors and economic burden of superficial and deep/organ space surgical site infections following pancreatectomy;Fadayomi;HPB (Oxford),2018